• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PAVmed Inc.

    9/23/24 8:46:15 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care
    Get the next $PAVM alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. _)*

     

    PAVMED INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    70387R403

    (CUSIP Number)

     

    August 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 70387R403   Schedule 13G   Page 2 of 6

     

    1

    NAMES OF REPORTING PERSONS

     

    Anthony Dubreville

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

     

    606,259

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    606,259

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    606,259

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

    CUSIP No. 70387R403   Schedule 13G   Page 3 of 6

     

    1

    NAMES OF REPORTING PERSONS

     

    Dubreville Family Trust

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

     

    556,807

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    556,807

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    556,807

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
    CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     

     

     

    CUSIP No. 70387R403   Schedule 13G   Page 4 of 6

     

    Item 1(a). Name of Issuer:
       
      PAVmed Inc. (the “Issuer”)
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      360 Madison Avenue, 25th Floor, New York, New York 10017
       
    Item 2(a). Name of Person Filing:
       
      This Statement is filed by Anthony Dubreville and The Dubreville Family Trust (the “Reporting Persons”). Mr. Dubreville is the trustee of The Dubreville Family Trust. As such, Mr. Dubreville may be deemed to have sole power to vote and dispose of the shares of the Issuer directly owned by The Dubreville Family Trust. Accordingly, the 606,259 shares of Common Stock reported as beneficially owned by Mr. Dubreville includes the 556,807 shares of Common Stock beneficially owned by The Dubreville Family Trust.
       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      The address of the principal business office of the Reporting Persons is c/o Graubard Miller, 405 Lexington Avenue, 44th Floor, New York, New York 10174.
       
    Item 2(c). Citizenship:
       
      Mr. Dubreville is a citizen of the United States of America. The Dubreville Family Trust is a trust formed under the laws of California.
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, par value $0.001 per share, of the Issuer (the “Common Stock”)
       
    Item 2(e). CUSIP Number:
       
      70387R403
       
    Item 3. If This Statement is Filed Pursuant to Rules 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act;
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act;
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act;
           
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ☐ A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J); or
           
      (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
           
      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________

     

     

     

     

    CUSIP No. 70387R403   Schedule 13G   Page 5 of 6

     

    Item 4. Ownership:
       
      (a) Amount Beneficially Owned:
         
        Mr. Dubreville: 606,259 shares
        The Dubreville Family Trust: 556,807 shares
         
      (b) Percent of Class:
         
        Mr. Dubreville: 5.5%
        The Dubreville Family Trust: 5.0%
         
      (c) Number of shares as to which the person has

     

      (i) Sole power to vote or direct the vote:
         
        Mr. Dubreville: 606,259 shares
        The Dubreville Family Trust: 556,807 shares
         
      (ii) Shared power to vote or direct the vote:
         
        Mr. Dubreville: 0 shares
        The Dubreville Family Trust: 0 shares
         
      (iii) Sole power to dispose or direct the disposition:
         
        Mr. Dubreville: 606,259 shares
        The Dubreville Family Trust: 556,807 shares
         
      (iv) Shared power to dispose or direct the disposition:
         
        Mr. Dubreville: 0 shares
        The Dubreville Family Trust: 0 shares

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      None.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
       
      None.
       
    Item 8. Identification and Classification of Members of the Group:
       
      None.
       
    Item 9. Notice of Dissolution of Group:
       
      None.
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 70387R403   Schedule 13G   Page 6 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 23, 2024

     

      /s/ Anthony Dubreville
      Anthony Dubreville
         
      THE DUBREVILLE FAMILY TRUST
         
      By: /s/ Anthony Dubreville
      Name: Anthony Dubreville
      Title: Trustee

     

     

     

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of PAVmed Inc. until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

     

    Dated: September 23, 2024

     

      /s/ Anthony Dubreville
      Anthony Dubreville
         
      THE DUBREVILLE FAMILY TRUST
         
      By: /s/ Anthony Dubreville
      Name: Anthony Dubreville
      Title: Trustee

     

     

    Get the next $PAVM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Tasso Partners, Llc claimed ownership of 2,574,350 shares (SEC Form 3)

    3 - PAVmed Inc. (0001624326) (Issuer)

    3/14/25 7:53:09 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Agrawal Sundeep

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/23/24 4:36:47 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Agrawal Sundeep

    4 - PAVmed Inc. (0001624326) (Issuer)

    9/20/24 4:13:39 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results

    Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million,and secured CAC meeting on Medicare LCD for EsoGuard to be held on September4 Veris Health completed 2Q25 financing, relaunched development of implantablephysiological monitor, and initiated integration steps to launch commercial phase withOSU-The James Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiari

    8/14/25 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for EsoGuard to be held on September 4 Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and

    8/13/25 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Participate in Upcoming Investor Conferences

    NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025Location: VirtualCanaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ETLocation: Boston, MAThe live and archived webcast of the Canacc

    8/5/25 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    SEC Filings

    View All

    PAVmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    8/14/25 8:00:39 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by PAVmed Inc.

    10-Q - PAVmed Inc. (0001624326) (Filer)

    8/13/25 8:04:24 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    7/30/25 8:00:28 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on PAVmed with a new price target

    Cantor Fitzgerald initiated coverage of PAVmed with a rating of Overweight and set a new price target of $8.00

    3/30/21 6:22:24 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lake Street Capital reiterated coverage on PAVmed with a new price target

    Lake Street Capital reiterated coverage of PAVmed with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    2/22/21 4:33:18 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

    Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

    9/16/24 4:30:00 PM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

    Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

    5/7/24 7:39:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    11/14/24 10:02:46 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    9/23/24 8:46:15 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    2/14/24 3:38:38 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $PAVM
    Financials

    Live finance-specific insights

    View All

    PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's secon

    7/31/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 fi

    7/30/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

    Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15th, at 8:30 AM EDT NEW YORK, May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical

    5/15/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care